FLASCO | Association Partnerships

August 08, 2021

Molecular testing practices and treatment decisions can vary for patients with non–small cell lung cancer. Cesar A. Perez, MD, and a group of other physicians discussed next steps in care for a patient with non–small cell lung cancer whose molecular test results revealed a RET mutation.

January 15, 2021

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

October 29, 2019

Winston Tan, MD, discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.

October 03, 2019

Winston Tan, MD, discusses the work of the Florida Society for Clinical Oncology, which helps improve the treatment of patients with all cancers.

June 26, 2019

The Rapid Integration Program, a training initiative for new physician’s assistants and nurse practitioners working in the field of oncology, is a Florida Society of Community Oncology (FLASCO) initiative that came from an ASCO meeting. Winston Tan, MD, of the Head and Neck Cancer Center at the Mayo Clinic in Jacksonville, Florida, speaking during the 2019 ASCO Annual Meeting, was in attendance at the 2016 ASCO Annual Meeting when the idea for a training program was first introduced.

June 11, 2019

Eric Harris, DO, hematologist/oncologist, Florida Cancer Specialists, gives Targeted Oncology an insider’s perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.